Cargando…

Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial

Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) antibody that has shown preclinical and clinical anticancer activity in cerebral glioblastoma multiforme (GBM). We conducted a phase II, single-arm, multicenter clinical trial to evaluate the benefit of adding nimotu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xiao-Jing, Li, Xian-Ming, Cai, Lin-Bo, Sun, Jian-Cong, Wang, Si-Yang, Wang, Xi-Cheng, Pang, Xiao-Lin, Deng, Mei-Ling, Chen, Fang-Fang, Wang, Zhi-Qiang, Chen, Fu-Rong, Zhang, Hong-Hong, Wang, Hui-Yun, Piedra, Patricia, Chen, Zhong-Ping, Lin, Jun, Wu, Shao-Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603389/ https://www.ncbi.nlm.nih.gov/pubmed/31289592 http://dx.doi.org/10.7150/jca.30123

Ejemplares similares

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
por: Joo, Jin-Deok, et al.
Publicado: (2012)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization
por: Li, Zhuang, et al.
Publicado: (2022)

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
por: Liang, Jun, et al.
Publicado: (2013)

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial
por: Yang, Xu, et al.
Publicado: (2021)

Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression
por: Gao, Yong-tao, et al.
Publicado: (2016)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis
por: Yin, An-an, et al.
Publicado: (2013)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma
por: Yang, Eryan, et al.
Publicado: (2022)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
por: Huang, Jianfeng, et al.
Publicado: (2017)

Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis
por: Liang, Zhong Guo, et al.
Publicado: (2018)

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
por: Wang, Chunyu, et al.
Publicado: (2015)

Clinical efficacy and safety of nimotuzumab plus chemotherapy in patients with advanced colorectal cancer: a retrospective analysis
por: Bai, Sai-xi, et al.
Publicado: (2020)

Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2018)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
por: Wang, Chun, et al.
Publicado: (2023)

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy
por: Zheng, Lin, et al.
Publicado: (2021)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
por: Zhang, Xiao-Ning, et al.
Publicado: (2021)

Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair
por: Qu, Yuan-yuan, et al.
Publicado: (2013)

Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review
por: Parenrengi, Muhammad A, et al.
Publicado: (2022)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
por: Metcalfe, Evrim, et al.
Publicado: (2016)

GADD45A plays a protective role against temozolomide treatment in glioblastoma cells
por: Wang, Hsiao-Han, et al.
Publicado: (2017)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
por: Yan, Tao, et al.
Publicado: (2011)

CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma
por: Wang, Shao-Ming, et al.
Publicado: (2021)

RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study
por: Beier, Christoph P, et al.
Publicado: (2009)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era
por: Paravati, Anthony J., et al.
Publicado: (2010)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
por: Areeb, Zammam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v4a49lk77ub3dajo91mhpfu0o8